Daewoong and AstraZeneca Korea to co-market Symbicort in Korea

Published: 2011-07-28 06:57:00

Updated: 2011-07-28 06:57:00

Daewoong Pharmaceutical and AstraZeneca Korea (AZK) Monday announced that the two companies have signed an agreement to co-market Symbicort (budesonide/formoterol) in Korea, in addition to Nexium.

Launched in 2001, Symbicort is a combination formulation used in the management of asthma and chr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK